Search

Displaying results 6641 - 6650 of 9322 in total
  1. Drug

    Ancriviroc

    go.drugbank.com/drugs/DB19773
    Experimental

    The usage of the INN stem '-viroc' in the name indicates that Ancriviroc is a CCR5 (Chemokine CC motif receptor 5) receptor antagonist. Ancriviroc has a monoisotopic molecular weight of 556.2 Da.

  2. Drug

    Diclofenac etalhyaluronate

    go.drugbank.com/drugs/DB20937
    Experimental

    The usage of the INN stem '-ac' in the name indicates that Diclofenac etalhyaluronate is a anti-inflammatory agent, ibufenac derivative.

  3. Drug

    D-JNKI-1

    go.drugbank.com/drugs/DB05660
    Investigational

    A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the

  4. Drug

    Xemilofiban

    go.drugbank.com/drugs/DB21058
    Experimental

    The usage of the INN stem '-fiban' in the name indicates that Xemilofiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  5. Drug

    Imdatifan

    go.drugbank.com/drugs/DB21643
    Experimental

    The usage of the INN stem '-tifan' in the name indicates that Imdatifan is a hypoxia inducible factor (HIF)-2alpha (HIF-2a) inhibitor. Imdatifan has a monoisotopic molecular weight of 385.05 Da.

  6. Drug

    Mesoheme

    go.drugbank.com/drugs/DB02577
    Experimental

    The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.

  7. Drug

    Malonyl-CoA

    go.drugbank.com/drugs/DB04524
    Experimental

    A coenzyme A derivative which plays a key role in the fatty acid synthesis in the cytoplasmic and microsomal systems.

  8. Drug

    Ulimorelin

    go.drugbank.com/drugs/DB12128
    Investigational

    Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility of the

  9. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  10. Drug

    PNT001

    go.drugbank.com/drugs/DB18375
    Investigational

    PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated Thr231-Pro232 motif in tau.